explore -WSS

explore

author：focus 2025-10-04 07:15:31 - browse：16819

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

WSS

RSV shot was 90% effective at preventing hospitalizations in kids

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Biden White House, tech companies launch new safeguards around emerging AI technology

Headspace, Meta partner to launch VR meditation app for Quest

Change Healthcare cyberattack prompts Medicare loan program

knowledge

explore

entertainment

Continuity nursing helped my family in our darkest PICU moments

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Tori Bowie and the unacceptable rates of Black maternal death

What it’s like to watch children die of measles

Activists slam private health insurers over coverage restrictions

Why Marc Tessier

Peter Hotez and the public health issue of online harassment

EMA weighs against approval for Mirati's lung cancer drug

Medical records are filled with copy

Change Healthcare cyberattack prompts Medicare loan program

focus

What is the Turing Test that determines if computers can think?

Change Healthcare payments predicted restored March 15

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Former medical device CEO who sold dummy, plastic parts convicted of fraud

What is artificial intelligence? Experts weigh in

Wikipedia

Wikipedia

hotspot

leisure time